Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Prasad A"'
Publikováno v:
OMICS: A Journal of Integrative Biology. 25:617-625
Genome regulation, temporal and spatial variations in cell function, continues to puzzle and interest life scientists who aim to unravel the molecular basis of human health and disease, not to mention plant biology and ecosystem diversity. Despite im
Autor:
Sneha M. Pinto, Thottethodi Subrahmanya Keshava Prasad, Vishalakshi Nanjappa, David Sidransky, Harsha Gowda, Aneesha Radhakrishnan, Aditi Chatterjee, Krishna Patel, Premendu P. Mathur, Ankit P. Jain, Remya Raja, Manish Kumar
Publikováno v:
OMICS
Resistance to cancer chemotherapy is a major global health burden. Epidermal growth factor receptor (EGFR) is a proven therapeutic target for multiple cancers of epithelial origin. Despite its overexpression in >90% of head and neck squamous cell car
Autor:
Manjusha Dixit, Biswaheree Mahananda, Ayaskanta Singh, Saroj Kanta Sahu, Shivaram Prasad Singh, Ananya Palo, J. Vinay
Publikováno v:
DNA and Cell Biology. 40:706-712
Serine protease inhibitor b5 (SERPINB5) is a tumor suppressor gene that plays a critical role in various cellular processes. In gallbladder cancer (GBC), SERPINB5's aberrant expression is reported ...
Autor:
Vishnu Sharma, Prasad V. Bharatam
Publikováno v:
Journal of Computational Biology. 28:43-59
Dihydrofolate reductase (DHFR) is a well-known enzyme of the folate metabolic pathway and it is a validated drug target for leishmaniasis. However, only a few leads are reported against Leishmania ...
Autor:
Thottethodi Subrahmanya Keshava Prasad, Sneha M. Pinto, Krishna R Murthy, Manjunath Dammalli, Kalpana Babu Murthy, Harsha Gowda, Gourav Dey, Raja Sekhar Nirujogi, Anil K. Madugundu, Bipin G. Nair
Publikováno v:
OMICS: A Journal of Integrative Biology. 21:114-122
Ophthalmology and visual health research have received relatively limited attention from the personalized medicine community, but this trend is rapidly changing. Postgenomics technologies such as proteomics are being utilized to establish a baseline
Publikováno v:
Antioxidants & Redox Signaling. 23:665-681
2-Deoxy-d-glucose (2-DG), a synthetic glycolytic inhibitor, is currently under clinical evaluation as a promising anticancer agent. However, 2-DG treatment in cancer cells activates prosurvival Akt signaling that might limit its clinical efficacy. Th